Objective: To assess the safety and efficacy of retroperitoneoscopy technique-assisted percutaneous nephrolithotomy (PCNL) used in the treatment of complexity horseshoe kidney (HSK) with renal stones. Methods: Between January 2012 and April 2015, 5 patients with renal stones in complexity HSK underwent retroperitoneoscopy technique-assisted PCNL. The perioperative data analyzed, included operation time, blood loss, incidence of complication rate, the stone-free rate (SFR), and so on. Results: All the patients successfully completed the operation without need for an open surgery. The mean operative time in which this procedure was done was 77.5 ± 20.6 min, the mean hemoglobin that was reduced was 2.5 ± 0.8 g/dl, the mean time to remove nephrostomy tube and retroperitoneal tube were 3.0 ± 1.0, 3.5 ± 1.0 days, respectively. The mean hospital stay was 7.0 ± 1.5 days. The SFR of all the patients was 80% (4/5). One patient who had residual stones (6 × 5 mm) in the middle pole underwent additional shock wave lithotripsy after the operation and no serious perioperative complications were noticed. Study limitations include small sample size and short follow-up time. Conclusions: Retroperitoneoscopy technique-assisted PCNL is a feasible, safe, and an effective alternative to laparoscopic pyelolithotomy for treating complexity HSK with renal stones, especially in a situation where the HSK is tightly wrapped by the surrounding organs.

Keywords:
Retroperitoneoscopy, Percutaneous nephrolithotomy, Horseshoe kidney, Renal stones
1.
Torricelli FC, Monga M: Urolithiasis in horseshoe kidney with duplex collecting system. Urology 2013;82:e20-e21.
2.
Majidpour HS, Yousefinejad V: Percutaneous management of urinary calculi in horseshoe kidneys. Urol J 2008;5:188-191.
3.
Etemadian M, Maghsoudi R, Abdollahpour V, Amjadi M: Percutaneous nephrolithotomy in horseshoe kidney: our 5-year experience. Urol J 2013;10:856-860.
4.
Skolarikos A, Binbay M, Bisas A, et al: Percutaneous nephrolithotomy in horseshoe kidneys: factors affecting stone-free rate. J Urol 2011;186:1894-1898.
5.
Lampel A, Hohenfellner M, Schultz-Lampel D, Lazica M, Bohnen K, Thürof JW: Urolithiasis in horseshoe kidneys: therapeutic management. Urology 1996;47:182-186.
6.
Atis G, Resorlu B, Gurbuz C, et al: Retrograde intrarenal surgery in patients with horseshoe kidneys. Urolithiasis 2013;41:79-83.
7.
Ray AA, Ghiculete D, D'A Honey RJ, Pace KT: Shockwave lithotripsy in patients with horseshoe kidney: determinants of success. J Endourol 2011;25:487-493.
8.
Stening SG, Bourne S: Supracostal percutaneous nephrolithotomy for upper pole caliceal calculi. J Endourol 1998;12:359-362.
9.
Desai M, Jain P, Ganpule A, Sabnis R, Patel S, Shrivastav P: Developments in technique and technology: the effect on the results of percutaneous nephrolithotomy for staghorn calculi. BJU Int 2009;104:542-548; discussion 548.
10.
Darabi Mahboub MR, Zolfaghari M, Ahanian A: Percutaneous nephrolithotomy of kidney calculi in horseshoe kidney. Urol J 2007;4:147-150.
11.
Viola D, Anagnostou T, Thompson TJ, Smith G, Moussa SA, Tolley DA: Sixteen years of experience with stone management in horseshoe kidneys. Urol Int 2007;78:214-218.
12.
El Ghoneimy MN, Kodera AS, Emran AM, Orban TZ, Shaban AM, El Gammal MM: Percutaneous nephrolithotomy in horseshoe kidneys: is rigid nephroscopy sufficient tool for complete clearance? A case series study. BMC Urol 2009;9:17.
13.
Shokeir AA, El-Nahas AR, Shoma AM, et al: Percutaneous nephrolithotomy in treatment of large stones within horseshoe kidneys. Urology 2004;64:426-429.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.